CVR 39308967Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)Secondary industries: Videregående uddannelse på universitetsniveau (854000)København SVFounded 5 Feb 2018
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about Aptol Pharma ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexEmployees
1
CVR registry, Dec 2025
Gross profit
2.4K
DKK, annual report 2024
-99.4% on 2023
Result
-131.3K
DKK, annual report 2024
Equity
-140.3K
DKK, annual report 2024
KGAA Holding ApSCVR 45756459, 33.3% to under 50% of capital and votes, since 1 Sep 2025
Tue Wenzel Kragstrup15% to under 20% of capital and votes, since 25 May 2022
and 3 moreOperating company
Dandex estimate: 1 employee registered in 2025; status is not activeKira Gerber Petersenuntil 28 Apr 2026
Equity was negative at 31 Dec 2024: -140.3K DKK. Dandex estimate, computed 10 Nov 2026.
15% to under 20% of capital and votesnotified 28 Feb 2025since 25 May 2022
10% to under 15% of capital and votessince 28 Nov 2025
CVR 3125531710% to under 15% of capital and votessince 28 Nov 2025
CVR 4575645933.3% to under 50% of capital and votessince 1 Sep 2025
15% to under 20% of capital and votesnotified 28 Feb 2025since 5 Feb 2018
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
33.3% to under 50% of capital and votesnotified 25 May 20225 Feb 2018 to 1 Sep 2025
CVR 3645424515% to under 20% of capital and votesnotified 28 Nov 20251 Mar 2020 to 28 Nov 2025
Decided by Dandex with fixed rules from the CVR register and the filed annual reports, not registered by the company. Each label links to its definition.
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
5 Feb 2018 to 10 Nov 2026.
Dec 2025, monthly: 1 employee, 1 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| FTE | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Monthly Oct 2019 to Dec 2025.
Latest Dec 2025, published 28 Mar 2026. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | Not reported | Not reported | Not reported |
| Gross profit | Not reported | Not reported | -422 | 414 | 2 |
| Operating profit | -441 | 0 | -422 | +342 | -128 |
| Result for the year | -2 | 0 | -334 | +308 | -131 |
| Equity | 50 | 50 | -317 | -9 | -140 |
| Total assets | 50 | 50 | 104 | 163 | 48 |
| Employees (average) | Not reported | Not reported | Not reported | 1 | 1 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | Not reportednote 1 | Not reportednote 1 | n.m.note 2 | n.m.note 2 | -99.4% |
| EBITDA | -441 | 0 | Not reportednote 3 | Not reportednote 3 | Not reportednote 3 |
| Employee growth (vækst i antal ansatte) | Not reportednote 4 | Not reportednote 4 | Not reportednote 4 | 0% | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | -50 | -50 | -17note 5 | -163note 5 | -28note 5 |
| Interest coverage (rentedækning) | -1.6x | n.m.note 6 | -1,778.7x | n.m.note 7 | -41.2x |
| Adjusted equity ratio (justeret soliditetsgrad) | 100%note 8 | 100%note 8 | -305.9%note 8 | -5.5%note 8 | -290.3%note 8 |
| Capex (investeringer i anlægsaktiver) | 0note 9 | 0note 9 | Not reportednote 10 | Not reportednote 10 | Not reportednote 10 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Definitions. No cash flow statement filed (class A and B are exempt).
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 7 Feb 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 29 Jan 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 5 Jul 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 1 Jan 2022
Annual report 2020
1 Jan 2020 to 31 Dec 2020, published 1 Jan 2021
Each registered value from the day it took effect, newest first.
From CVR, read 10 Nov 2026. Text such as the signing rule and purpose is shown as registered.
17 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Konkursdekret afsagt 28.04.2026 af Sø- og Handelsrettens Skifteretsafdeling
Bestyrelse:
Fratrådte:
Kira Gerber Astakhova, den 28.04.2026, Peter Andreas Nicolai Reumert Wagtmann, den 28.04.2026.
Direktion:
Fratrådte:
Kira Gerber Astakhova, den 28.04.2026.
Revision:
Bestyrelse:
Fratrådte:
Mads Hartvig Clausen, (formand), den 28.11.2025.
Bestyrelse:
Fratrådte:
Mads Hartvig Clausen, den 31.07.2025, Anders Dyhr Dombernowsky-Toft, (formand), den 31.07.2025.
Tiltrådte:
Mads Hartvig Clausen, (formand), den 31.07.2025.
Vedtægter ændret: 28.02.2025
Kapitalforhøjelsen er besluttet den 28.02.2025.
kr. 2.500,00, indbetalt ved konvertering af gæld, kurs 100,00.
Kapitalen udgør herefter kr. 52.500,00.
Vedtægter ændret: 04.11.2024
Vedtægter ændret: 29.10.2024
Vedtægter ændret: 14.03.2024
Vedtægter ændret: 13.03.2024
Formål ændret: Selskabets formål er at udvikle nye lægemidler alene eller i partnerskaber.
Vedtægter ændret: 12.09.2023
Vedtægter ændret: 21.08.2023
Selskabet tegnes af en direktør.
Vedtægter ændret: 25.05.2022
Nyt navn: Aptol Pharma ApS
Slettet binavn: Integrated Biomedical Technologies ApS
Vedtægter ændret: 13.12.2019
Nyt navn: IBIO TECH ApS
Nyt binavn: Integrated Biomedical Technologies ApS
Slettet binavn: IBIO TECH ApS
Bestyrelse:
Fratrådte:
Kira Astakhova, (formand), den 13.12.2019.
Tiltrådte:
Kira Astakhova, den 13.12.2019.
Formål ændret: Selskabets formål er at drive virksomhed der vil udvikle nye terapeutiske biokonjugater og levere avancerede undervisnings programmer til kunder på universitetsniveau, samt de kunder der ønsker at fremstille, bestille og afprøve sådanne biokonjugater.
Ny adresse: c/o Kira Astakhova, Thad Jones Vej 6, st. th, 2450 København SV
Binavne: IBIO TECH ApS.
Stiftelsesdato: 05.02.2018.
Virkningsdato: 05.02.2018.
Seneste vedtægtsdato: 05.02.2018.
Kapital:
kr. 50.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 50.000,00 til kurs 100,00, fuldt indbetalt.
Stifter:
Kira Astakhova, den 05.02.2018.
Bestyrelse:
Kira Astakhova (formand), den 05.02.2018.
Direktion:
Kira Astakhova, den 05.02.2018.
Virksomheden tegnes af en direktør..
Første regnskabsår:
05.02.2018 - 31.12.2018.
Regnskabsår:
01.01 - 31.12.
Formål:
IBIO TECH er en højteknologisk virksomhed, der har til formål at yde rådgivning om forskningsteknologier, med fokus på biomedicinske anvendelser af nanobiokonjugater. Udover dette har IBIO TECH et mål at tiltrække tilskud og etablere en syntese af nye lægemidler til terapi af humane autoimmune sygdomme.
1 registered in CVR.
P-number 1023319167Thad Jones Vej 6, 2450 København SV
No other current company drawn.
